<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28989/tedopi-a-patented-combination-of-10-neo-epitopes-tedopi-is-being-evaluated-in-nsclc-after-checkpoint-inhibitor-failure?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

TEDOPI: A Patented Combination Of 10 Neo-Epitopes. TEDOPI...

Name: TEDOPI: A Patented Combination Of 10 Neo-Epitopes. TEDOPI...
Uploaded: 2019-06-04T06:44:54
Duration: 1 min 24 s
Description: Alexis Peyroles MBA CEO Of OSE Immunotherapeutics Discusses TEDOPI: A Patented Combination Of 10 Neo-Epitopes. TEDOPI Is Being Evaluated In NSCLC After Checkpoint Inhibitor Failure.

TEDOPI: A Patented Combination Of 10 Neo-Epitopes. TEDOPI Is Being Evaluated In NSCLC After Checkpoint Inhibitor Failure

00:01:24

Annual Meeting

3 years 84 Views

Share Add to Report 0 0

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28989/tedopi-a-patented-combination-of-10-neo-epitopes-tedopi-is-being-evaluated-in-nsclc-after-checkpoint-inhibitor-failure?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/videoEmbed/28989/tedopi-a-patented-combination-of-10-neo-epitopes-tedopi-is-being-evaluated-in-nsclc-after-checkpoint-inhibitor-failure?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/videoEmbed/28989/tedopi-a-patented-combination-of-10-neo-epitopes-tedopi-is-being-evaluated-in-nsclc-after-checkpoint-inhibitor-failure?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://oncologytube.com/v/28989?channelName=AnnualCancerMeeting"><img src="https://oncologytubecom.cdn.ypt.me/videos/video_190604184454_c4c6/video_190604184454_c4c6.jpg?cache=15669162541678829655">TEDOPI: A Patented Combination Of 10 Neo-Epitopes. TEDOPI Is Being Evaluated In NSCLC After Checkpoint Inhibitor Failure</a>

Link (BBCode):

[url=https://oncologytube.com/v/28989?channelName=AnnualCancerMeeting][img]https://oncologytubecom.cdn.ypt.me/videos/video_190604184454_c4c6/video_190604184454_c4c6.jpg?cache=15669162541678829655[/img]TEDOPI: A Patented Combination Of 10 Neo-Epitopes. TEDOPI Is Being Evaluated In NSCLC After Checkpoint Inhibitor Failure[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Immunotherapy

Description:

Alexis Peyroles MBA CEO Of OSE Immunotherapeutics Discusses TEDOPI: A Patented Combination Of 10 Neo-Epitopes. TEDOPI Is Being Evaluated In NSCLC After Checkpoint Inhibitor Failure.